ERBB2 and breast cancer: reported that radiomics combining contrast-enhanced spectral mammography performed well in predicting histological subtypes of breast cancer, with accuracies of 90.87%, 83.79%, and 84.80% in discriminating HER2+/HER2−, ER+/ER−, and Ki67+/Ki67− breast cancer, respectively (44).